Galanin decreases proliferation of PC12 cells and induces apoptosis via its subtype 2 receptor (GalR2)

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 7, 2008, Pages 2717-2722

  Tofighi, R ^a   Joseph, B ^a   Xia, S ^a   Xu, Z Q D ^a   Hamberger, B ^a   Hokfelt T ^a   Ceccatelli, S ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adrenal medulla; Galanin receptor; Neuropeptide; Pheochromocytoma; Tumor

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CASPASE; GALANIN; GALANIN RECEPTOR 2; NEUROPEPTIDE; PROTEIN BAD; PROTEIN INHIBITOR; PROTEIN KINASE B; GALANIN RECEPTOR 1; PHOSPHATIDYLINOSITOL 3 KINASE;

ADRENAL MEDULLA; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FUNCTIONAL PROTEOMICS; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; NONHUMAN; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR INTRINSIC ACTIVITY; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; WESTERN BLOTTING; ANIMAL; CELL STRAIN; DRUG EFFECT; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

RATTUS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; APOPTOSIS; CASPASES; CELL PROLIFERATION; ENZYME ACTIVATION; GALANIN; GENE EXPRESSION REGULATION; HUMANS; PC12 CELLS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RECEPTOR, GALANIN, TYPE 1; RECEPTOR, GALANIN, TYPE 2; SIGNAL TRANSDUCTION;

EID: 40649089094     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0712300105     Document Type: Article

References (66)

1. Tatemoto K, Rokaeus A, Jornvall H, McDonald TJ, Mutt V (1983) Galanin: A novel biologically active peptide from porcine intestine. FEBS Lett 164:124-128.
2. Liu HX, Hokfelt T (2002) The participation of galanin in pain processing at the spinal level. Trends Pharmacol Sci 23:468-474.
3. Wiesenfeld-Hallin Z, Xu XJ (2001) Neuropeptides in neuropathic and inflammatory pain with special emphasis on cholecystokinin and galanin. Eur J Pharmacol 429:49-59.
4. Xu XJ, Hokfelt T, Bartfai T, Wiesenfeld-Hallin Z (2000) Galanin and spinal nociceptive mechanisms: recent advances and therapeutic implications. Neuropeptides 34:137-147.
5. Kalra SP, Horvath TL (1998) Neuroendocrine interactions between galanin, opioids, and neuropeptide Y in the control of reproduction and appetite. Ann NY Acad Sci 863:236-240.
6. Leibowitz SF (2005) Regulation and effects of hypothalamic galanin: Relation to dietary fat, alcohol ingestion, circulating lipids and energy homeostasis. Neuropeptides 39:327-332.
7. Holmes FE, Mahoney SA, Wynick D (2005) Use of genetically engineered transgenic mice to investigate the role of galanin in the peripheral nervous system after injury. Neuropeptides 39:191-199.
8. Counts SE, et al. (2001) Galanin: Neurobiologic mechanisms and therapeutic potential for Alzheimer's disease. CNS Drug Rev 7:445-470.
9. Mazarati A, Lu X (2005) Regulation of limbic status epilepticus by hippocampal galanin type 1 and type 2 receptors. Neuropeptides 39:277-280.
10. Berger A, et al. (2005) Galanin and galanin receptors in human cancers. Neuropeptides 39:353-359.
11. Kogner P (1995) Neuropeptides in neuroblastomas and ganglioneuromas. Progr Brain Res 104:325-338.
12. Barakat MT, Meeran K, Bloom SR (2004) Neuroendocrine tumours. Endocrine-Related Cancer 11:1-18.
13. Reubi JC (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24:389-427.
14. Branchek TA, Smith KE, Gerald C, Walker MW (2000) Galanin receptor subtypes. Trends Pharmacol Sci 21:109-117.
15. Iismaa TP, Shine J (1999) Galanin and galanin receptors. Results Problems Cell Differ 26:257-291.
16. Lang R, Gundlach AL, Kofler B (2007) The galanin peptide family: Receptor pharmacology, pleiotropic biological actions, and implications in health and disease. Pharmacol Therapeutics 115:177-207.
17. Wang S, Hwa J, Varty G (2000) Galanin receptors and their therapeutic potential Emerging Drugs 5:415-440.
18. Waters SM, Krause JE (2000) Distribution of galanin-1, -2 and -3 receptor messenger RNAs in central and peripheral rat tissues. Neuroscience 95:265-271.
19. O'Donnell DM, F., Hoffert C, Hulatsch D, Pelletier M, Walker P, Ahmad S (2003) in Handbook of Chemical Anatomy, Peptide Receptors (II, eds Quirion R, Bjorklund A, Hökfelt T (Elsevier, Amsterdam), pp 195-224.
20. Berger A, et al. (2004) Galanin receptor subtype GalR2 mediates apoptosis in SH-SY5Y neuroblastoma cells. Endocrinology 145:500-507.
21. Wittau N, et al. (2000) The galanin receptor type 2 initiates multiple signaling pathways in small cell lung cancer cells by coupling to G(q), G(i) and G(12) proteins. Oncogene 19:4199-4209.
22. Elder EE, Elder G, Larsson C (2005) Pheochromocytoma and functional paraganglioma syndrome: No longer the 10% tumor. J Surg Oncol 89:193-201.
23. Hoehner JC, et al. (1998) Developmental gene expression of sympathetic nervous system tumors reflects their histogenesis. Lab Invest 78:29-45.
24. Edstrom Elder E, Hjelm Skog AL, Hoog A, Hamberger B (2003) The management of benign and malignant pheochromocytoma and abdominal paraganglioma. Eur J Surg Oncol 29:278-283.
25. Stenstrom G, Svardsudd K (1986) Pheochromocytoma in Sweden 1958-1981: An analysis of the National Cancer Registry data. Acta Medica Scand 220:225-232.
26. Sutton MG, Sheps SG, Lie JT (1981) Prevalence of clinically unsuspected pheochromocytoma: Review of a 50-year autopsy series. Mayo Clinic Proc 56:354-360.
27. Xia S, et al. (2004) Visualization of a functionally enhanced GFP-tagged galanin R2 receptor in PC12 cells: Constitutive and ligand-induced internalization. Proc Natl Acad Sci USA 101:15207-15212.
28. Gorman AM, Orrenius S, Ceccatelli S (1998) Apoptosis in neuronal cells: Role of caspases. NeuroReport 9:R49-R55.
29. Li P, et al. (1997) Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91:479-489.
30. Brecht S, Buschmann T, Grimm S, Zimmermann M, Herdegen T (1997) Persisting expression of galanin in axotomized mamillary and septal neurons of adult rats labeled for c-Jun and NADPH-diaphorase. Brain Res 48:7-16.
31. Fathi Z, et al. (1998) Molecular characterization, pharmacological properties and chromosomal localization of the human GALR2 galanin receptor. Brain Res. 58:156-169.
32. Fathi Z, et al. (1997) Cloning, pharmacological characterization and distribution of a novel galanin receptor. Brain Res 51:49-59.
33. Smith KE, et al. (1997) Expression cloning of a rat hypothalamic galanin receptor coupled to phosphoinositide turnover. J Biol Chem 272:24612-24616.
34. Wang S, et al. (1998) Differential intracellular signaling of the GalR1 and GalR2 galanin receptor subtypes. Biochemistry 37:6711-6717.
35. Tsujimoto Y (1998) Role of Bcl-2 family proteins in apoptosis: Apoptosomes or mitochondria? Genes Cells 3:697-707.
36. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ (1996) Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87:619-628.
37. Lu X, Lundstrom L, Bartfai T (2005) Galanin (2-11) binds to GalR3 in transfected cell lines: limitations for pharmacological definition of receptor subtypes. Neuropeptides 39:165-167.
38. Maddika S, et al. (2007) Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Update 10:13-29.
39. Cardone MH, et al. (1998) Regulation of cell death protease caspase-9 by phosphorylation. Science 282:1318-1321.
40. Orrenius S, Zhivotovsky B, Nicotera P (2003) Regulation of cell death: the calcium-apoptosis link. Nat Rev 4:552-565.
41. Wang HG, et al. (1999) Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science 284:339-343.
42. Li R, Waga S, Hannon GJ, Beach D, Stillman B (1994) Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 371:534-537.
43. Waga S, Hannon GJ, Beach D, Stillman B (1994) The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369:574-578.
44. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ (1998) The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 396:177-180.
45. Eastham JA, et al. (1995) In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 55:5151-5155.
46. Joshi US, et al. (1998) Inhibition of tumor cell growth by p21WAF1 adenoviral gene transfer in lung cancer. Cancer Gene Ther 5:183-191.
47. Shibata MA, Yoshidome K, Shibata E, Jorcyk CL, Green JE (2001) Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21. Cancer Gene Ther 8:23-35.
48. Suzuki A, et al. (2000) Procaspase 3/p21 complex formation to resist fas-mediated cell death is initiated as a result of the phosphorylation of p21 by protein kinase A. Cell Death Differ 7:721-728.
49. Los M, Stroh C, Janicke RU, Engels IH, Schulze-Osthoff K (2001) Caspases: more than just killers? Trends Immunol 22:31-34.
50. Henson BS, et al. (2005) Galanin receptor 1 has anti-proliferative effects in oral squamous cell carcinoma. J Biochem 280:22564-22571.
51. Kanazawa T, et al. (2007) Galanin and galanin receptor type 1 suppress proliferation in squamous carcinoma cells: Activation of the extracellular signal regulated kinase pathway and induction of cyclin-dependent kinase inhibitors. Oncogene 26:5762-5771.
52. Costa T, Herz A (1989) Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci USA 86:7321-7325.
53. Leterrier C, Bonnard D, Carrel D, Rossier J, Lenkei Z (2004) Constitutive endocytic cycle of the CB1 cannabinoid receptor. J Biol Chem 279:36013-36021.
54. Signoret N, et al. (1997) Phorbol esters and SDF-1 induce rapid endocytosis and down modulation of the chemokine receptor CXCR4. J Cell Biol 139:651-664.
55. Bauer FE, et al. (1986) Localization and molecular forms of galanin in human adrenals: elevated levels in pheochromocytomas. J Clin Endocrinol Metab 63:1372-1378.
56. Tuechler C, Hametner R, Jones N, Jones R, Iismaa TP, Sperl W, Kofler B (1998) Galanin and galanin receptor expression in neuroblastoma. Ann NY Acad Sci 863:438-441.
57. Perel Y, et al. (2002) Galanin and galanin receptor expression in neuroblastic tumours: correlation with their differentiation status. Br J Cancer 86:117-122.
58. Bronshtein ME, Smirnova EA, Iur'eva NP (1988) Catecholamine-producing tumors of the chromaffin tissue. Morphological and ultrastructural characteristics. Voprosy onkologii 34:826-832.
59. Raikhlin NT, et al. (2002) Ultrastructural criteria of malignancy of adrenal medullary tumor. Bull Exp Biol Med 134:64-68.
60. Wynick D, Bacon A (2002) Targeted disruption of galanin:Newinsights from knock-out studies. Neuropeptides 36:132-144.
61. Hawes JJ, Narasimhaiah R, Picciotto MR (2006) Galanin and galanin-like peptide modulate neurite outgrowth via protein kinase C-mediated activation of extracellular signal-related kinase. Eur J Neurosci 23:2937-2946.
62. Elliott-Hunt CR, Pope RJ, Vanderplank P, Wynick D (2007) Activation of the galanin receptor 2 (GalR2) protects the hippocampus from neuronal damage. J Neurochem 100:780-789.
63. Pirondi S, et al. (2005) The galanin-R2 agonist AR-M1896 reduces glutamate toxicity in primary neural hippocampal cells. J Neurochem 95:821-833.
64. Liu HX, et al. (2001) Receptor subtype-specific pronociceptive and analgesic actions of galanin in the spinal cord: Selective actions via GalR1 and GalR2 receptors. Proc Natl Acad Sci USA 98:9960-9964.
65. Dare E, et al. (2002) Styrene 7,8-oxide induces caspase activation and regular DNA fragmentation in neuronal cells. Brain Res 933:12-22.
66. Gorman AM, Hirt UA, Zhivotovsky B, Orrenius S, Ceccatelli S (1999) Application of a fluorometric assay to detect caspase activity in thymus tissue undergoing apoptosis in vivo. J Immunol Methods 226:43-48.